Search
Omeros Corp
OMERAdd to Watchlist
9.280USD
-0.130-1.38%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
668.15MMarket Cap
7.12P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.38%
5 Days
+7.04%
1 Month
-9.46%
6 Months
-43.35%
Year to Date
-45.97%
1 Year
+190.00%
Key Figures
9.410Open
9.620High
1.38MVolume
7.12P/E TTM
LossP/E Dynamic
--Dividend TTM
1.91%Turnover Ratio
9.410Prev. Close
9.000Low
8.46MTurnover
LossP/E Static
-10.55P/B
0.00%Div Yield TTM
32.23%ROA
17.65052wk High
0.63Volume Ratio
-156.81MNet Profit
72.00MShares
1.3031EPS TTM
2.55Beta
-576.33%ROE
2.95052wk Low
6.59%Amplitude
94.07%Gross Margin
668.15MMarket Cap
-1.80Reward/Risk
4.55%Risk Rate
TradingKey Stock Score of Omeros Corp
Currency: USD Updated: 2026-07-02Key Insights
Omeros Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Omeros Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Omeros Corp Highlights
StrengthsRisks
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Overvalued
The company’s latest PE is 7.12, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 38.03M shares, increasing 4.51% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 79.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
44.000
Target Price
+367.59%
Upside Space
Omeros Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Omeros Corp Info
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Ticker SymbolOMER
CompanyOmeros Corp
CEODemopulos (Gregory A)
Websitehttps://www.omeros.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Omeros Corp (OMER)?
The current price of Omeros Corp (OMER) is 9.28.
What is the symbol of Omeros Corp?
The ticker symbol of Omeros Corp is OMER.
What is the 52-week high of Omeros Corp?
The 52-week high of Omeros Corp is 17.65.
What is the 52-week low of Omeros Corp?
The 52-week low of Omeros Corp is 2.95.
What is the market capitalization of Omeros Corp?
The market capitalization of Omeros Corp is 668.15M.
Is Omeros Corp (OMER) currently rated as Buy, Hold, or Sell?
According to analysts, Omeros Corp (OMER) has an overall rating of Buy, with a price target of 44.00.
What is the Earnings Per Share (EPS TTM) of Omeros Corp (OMER)?
The Earnings Per Share (EPS TTM) of Omeros Corp (OMER) is -0.05.